Melanostatin (MIF-1) is a naturally occurring neuropeptide acting as a positive allosteric modulator (PAM) of dopamine D2 receptors (D2R), underscoring its potential for therapeutic use in central nervous system disorders associated with dopaminergic dysregulation, including depression, drug addiction, restless legs syndrome, tardive dyskinesia, and Parkinson's disease. In this work, a new series of MIF-1 analogs using l-pipecolic acid as an l-proline surrogate was synthesized and pharmacologically evaluated by functional assays at the D2R. In this series, methyl l-pipecolyl-l-leucylglycinate (9) was found to exhibit superior performance compared to MIF-1 by promoting a 4.1- and 4.2-fold increase of dopamine potency at 0.01 and 1 nM, respectively. In silico conformational studies demonstrate that 9 preferentially adopts a γ-turn, corroborating that neither the C-terminal carboxamide nor the postulated type II β-turn conformation is required for PAM activity. Toxicological assays in human dopaminergic SH-SY5Y neuronal cells show that this compound exhibits no significant toxicity up to 100 μM in the MTT reduction and neutral red uptake assays.
A series of bicyclic-based Glypromate conjugates with reduction of protein aggregation elicited by Aβ25–35 and neuroprotective activity against paraquat-induced toxicity is reported, paving the way for the discovery of novel neurotherapeutics.
4 November 2024 in ACS Sustainable Chemistry & Engineering
Melanostatin (MIF-1) is an endogenous tripeptide that acts as a positive allosteric modulator (PAM) of the dopamine D2 receptors (D2R), making it a valuable pharmacological lead for the treatment of dopamine-related disorders of the central nervous system (CNS). In this study, a novel series of MIF-1 derivatives was synthesized and pharmacologically evaluated to investigate the influence of ring flexibility and stereochemistry on PAM activity. For this purpose, the alicyclic β-amino acids (1R,2S)-2-aminocyclopentane-1-carboxylic acid (cispentacin) and its unsaturated precursor, (1R,2S)-2-aminocyclopent-3-ene-1-carboxylic acid, were used as proline surrogates. The results obtained showed that cispentacin-based derivatives 8b and 9b displayed PAM activity at 10 pM, significantly reducing the EC50 of dopamine by 4.34- and 4.22-fold, respectively (8b: EC50 = 20.08 ± 3.95 nM; 9b: EC50 = 20.61 ± 4.60 nM). At 1 nM, 8b further decreased the EC50 of dopamine by 9.20-fold (EC50 = 9.47 ± 5.02 nM) and, at higher concentrations (10 and 100 μM), it activated the D2R in the absence of dopamine, representing the first-in-class MIF-1-based ago-allosteric modulator of the D2R. Cytotoxicity assays in human dopaminergic-differentiated SH-SY5Y cells showed that neither 8b nor 9b exhibited cytotoxic effects at 100 μM, as assessed by both the MTT reduction and neutral red uptake assays, supporting their favorable toxicological profiles. Overall, these findings demonstrate that a fine-tuned interplay between ring flexibility and stereochemistry is a key determinant in generating effective PAM of the D2R, providing a framework for the future design of MIF-1-based modulators targeting Parkinson's disease and other dopamine-related CNS disorders.
12 September 2026 in ACS Medicinal Chemistry Letters
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with neuroprotective effects, whose dependence on MAO-B inhibition remains unclear. Here, indane-to-azaindane rasagiline isosteres (rac-2a and rac-2b) were developed to investigate whether neuroprotection can be decoupled from MAO-B inhibition. Direct regioselective oxidation of 4-azaindane catalyzed by Mn(OAc)2/tBuOOH afforded the key 4-azaindan-1-one intermediate (6a). In paraquat-insulted dopaminergic differentiated SH-SY5Y cells, both analogs showed neuroprotection at 10 and 100 μM, with rac-2b outperforming rasagiline. The azaindane analogs displayed markedly reduced MAO-B inhibition and no time-dependent inhibition. These findings demonstrate that rasagiline neuroprotection can be dissociated from MAO-B inhibition, supporting azaindane bioisosterism for exploring MAO-independent neuroprotection.